Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 12, 2012 - Issue 3
Submit an article Journal homepage
143
Views
6
CrossRef citations to date
0
Altmetric
Review

Cost–effectiveness of TNF-α inhibition in active ankylosing spondylitis: a systematic appraisal of the literature

Timm D Kirchhoff Working Group Health Economics in Rheumatology, Clinic for Immunology and Rheumatology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany; Working Group Health Economics in Rheumatology, Clinic for Immunology and Rheumatology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
,
Thomas Mittendorf Institute for Risk and Insurance, Center for Health Economics, Königsworther Platz 1, 30167 Hannover, Germany; Herescon GmbH, Königsworther Str. 2, 30167 Hannover, Germany; Institute for Risk and Insurance, Center for Health Economics, Königsworther Platz 1, 30167 Hannover, Germany; Herescon GmbH, Königsworther Str. 2, 30167 Hannover, Germany
,
Reinhold E Schmidt Clinic for Immunology and Rheumatology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany; Clinic for Immunology and Rheumatology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
,
Alexandra Jablonka Working Group Health Economics in Rheumatology, Clinic for Immunology and Rheumatology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany; Clinic for Immunology and Rheumatology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany; Working Group Health Economics in Rheumatology, Clinic for Immunology and Rheumatology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany; Clinic for Immunology and Rheumatology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
&
Sonja Merkesdal Working Group Health Economics in Rheumatology, Clinic for Immunology and Rheumatology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany; Working Group Health Economics in Rheumatology, Clinic for Immunology and Rheumatology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. [email protected]
Pages 307-317 | Published online: 09 Jan 2014

References

  • Landewé R, Dougados M, Mielants H, van der Tempel H, van der Heijde D. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann. Rheum. Dis. 68(6), 863–867 (2009).
  • Reed MR, Taylor AL. Tumour necrosis factor inhibitors in ankylosing spondylitis. Intern. Med. J. 38(10), 781–789 (2008).
  • Boonen A, Brinkhuizen T, Landewé R, van der Heijde D, Severens JL. Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. Ann. Rheum. Dis. 69(6), 1123–1128 (2010).
  • Boonen A. A review of work-participation, cost-of-illness and cost–effectiveness studies in ankylosing spondylitis. Nat. Clin. Pract. Rheumatol. 2(10), 546–553 (2006).
  • Braun J, Bollow M, Remlinger G et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 41(1), 58–67 (1998).
  • Johnsen K, Gran JT, Dale K, Husby G. The prevalence of ankylosing spondylitis among Norwegian Samis (Lapps). J. Rheumatol. 19(10), 1591–1594 (1992).
  • van der Heijde D, Sieper J, Maksymowych WP et al.; Assessment of Spondyloarthritis International Society. 2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann. Rheum. Dis. 70(6), 905–908 (2011).
  • Graf von der Schulenburg JM, Greiner W, Jost F et al.; Hanover Consensus Group. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health 11(4), 539–544 (2008).
  • Kobelt G, Andlin-Sobocki P, Brophy S, Jönsson L, Calin A, Braun J. The burden of ankylosing spondylitis and the cost–effectiveness of treatment with infliximab (Remicade). Rheumatology 43(9), 1158–1166 (2004).
  • Kobelt G, Andlin-Sobocki P, Maksymowych WP. The cost–effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada. J. Rheumatol. 33(4), 732–740 (2006).
  • Kobelt G, Sobocki P, Sieper J, Braun J. Comparison of the cost–effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials. Int. J. Technol. Assess. Health Care 23(3), 368–375 (2007).
  • Kobelt G, Sobocki P, Mulero J, Gratacos J, Collantes-Estevez E, Braun J. The cost–effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data. Scand. J. Rheumatol. 37(1), 62–71 (2008).
  • Boonen A, van der Heijde D, Severens JL et al. Markov model into the cost–utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis. Ann. Rheum. Dis. 65(2), 201–208 (2006).
  • Ara RM, Reynolds AV, Conway P. The cost–effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK. Rheumatology 46(8), 1338–1344 (2007).
  • Neilson AR, Sieper J, Deeg M. Cost–effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany. Rheumatology 49(11), 2122–2134 (2010).
  • Botteman MF, Hay JW, Luo MP, Curry AS, Wong RL, van Hout BA. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom. Rheumatology 46(8), 1320–1328 (2007).
  • McLeod C, Bagust A, Boland A et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol. Assess. 11(28), 1–158, iii (2007).
  • Baeten D, Sieper J, Emery P et al. The anti-IL17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis. Arthritis Rheum. 62, 2840–2841 (2010)
  • Song IH, Heldmann F, Rudwaleit M et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum. 62(5), 1290–1297 (2010).
  • Santra G, Sarkar RN, Phaujdar S, Banerjee S, Siddhanta S. Assessment of the efficacy of pamidronate in ankylosing spondylitis: an open prospective trial. Singapore Med. J. 51(11), 883–887 (2010).
  • Baraliakos X, Listing J, Fritz C et al. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years – early clinical response predicts long-term outcome. Rheumatology 50(9), 1690–1699 (2011).
  • Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann. Rheum. Dis. 63(6), 665–670 (2004).
  • Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann. Rheum. Dis. 59(6), 428–433 (2000).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.